Clinical Trial Update: Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab plus sargramostim (GM-CSF) in patients with chronic lymphocytic leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituximab (rituximab)
• Sargramostim (GM-CSF) (sargramostim)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2018-09-19